Pricing Log in Create free account
Saturday 17 October 2026 Export VRAX’s income statement to Excel — free account

Virax Biolabs Group Limited

VRAX Healthcare Biotechnology

Virax Biolabs Group Limited’s revenue for fiscal 2026 (year ended March 2026) was $12,400.00, up 96.8% from fiscal 2025.

1.45 0.17 −10.49%
Market cap
$2.2M
P/E
0.0×
Fwd P/E
−0.9×
Dividend yield
—
F-score
6/9
Altman Z
−5.30
Beneish M
−9.96
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 13.81%

Capital & Financial Ratios $m

Market Cap 2.18
Revenue —
Net Income (16.20)
Free Cash Flow (15.11)
Net Debt (6.41)
Current Ratio 9.97 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.89) (negative: loss-making)
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 51.60% (at or above 15%: strong)
Next Y EPS Growth 40.00% (at or above 15%: strong)
Next Y revenue growth (67.74%) (below 0%: weak)
Next 5Y EPS Growth 57.19% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/FCF against its own 10 years 63.05%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 9 4 4 6
Receivables — 0 0 0
Inventory — 0 0 0
Other — — — —
10 4 5 7
2023 2024 2025 2026
Payables 1 0 1 1
ST’ Debt 0 — 0 0
Other — — — —
1 0 1 1

Compound Annual Growth %

10y 5y 3y
Sales — (36.88%) 12.97%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% (6.26%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — 0
’25 — — — — 0
’24 — — — — 0
’23 — — — — 0
’21 — — — — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — (5)
’25 — — — — (5)
’24 — — — — (6)
’23 — — — — (4)
’22 — — — — (1)
’21 — — — — (1)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 (5) — (3) — (5)
’25 (5) — (2) — (5)
’24 (7) — (4) — (7)
’23 (4) — (2) — (4)
’22 (1) — 0 — (1)
’21 (1) — — — (1)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — (12.64)
’25 — — — — (40.50)
’24 — — — — (84.00)
’23 — — — — (127.50)
’22 — — — — (45.75)
’21 — — — — (69.98)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low — — — — — 135.00 32.00 15.00 7.75 1.38

Analyst estimates 2027–2029

Powerpack
High — — — — — 7,250.00 400.00 225.00 80.00 13.35
People
People Employees — — — — — 5 11 17 19 26
Revenue/emp, $m — — — 0.00 0.00 0.00 0.00 0.01 0.00 0.00
Income, $m
Income, $m Revenue — — — 0 0 — 0 0 0 0
Gross margin, % — — — (7.67) (7.59) — (16.28) 32.35 (842.86) 62.10
EBT — — — (1) (1) (2) (5) (7) (6) (6)
EBT margin, % — — — (543.54) (543.54) 0.00 (63,462.79) (4,308.89) (98,474.60) (47,841.94)
Net income — — — 0 (1) (2) (5) (7) (6) (5)
Depreciation — — — — — — — 0 0 0
Per share, $
Per share, $ Revenue — — — 0.11 12.90 0.00 0.20 1.95 0.04 0.03
Earnings — — — (0.62) (69.98) (45.75) (127.50) (84.00) (40.50) (12.64)
Cash flow — — — (0.65) (61.48) (21.20) (98.35) (77.89) (30.59) (11.62)
Capex — — — 0.00 0.00 0.00 (4.20) (14.52) (4.05) (0.64)
Free cash flow — — — (0.65) (61.48) (21.20) (102.55) (92.41) (34.63) (12.27)
Book value — — — (0.73) (86.65) (31.25) 209.51 64.07 36.61 18.45
Shares, m — — — 1 0 0 0 0 0 0
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 — 0.00 0.00 0.00 0.00
P/S — — — 0.00 0.00 — 0.00 0.00 0.00 0.00
P/B — — — 0.00 0.00 — 0.00 0.00 0.00 0.00
EV/Sales — — — 0.00 0.00 — 0.00 0.00 0.00 0.00
EV/FCF — — — 0.00 0.00 — 1.22 0.20 0.23 0.42
Cash, $m
Cash, $m Operating cash flow — — — (1) (1) (1) (4) (6) (5) (5)
Capex — — — — — — 0 (1) (1) 0
Free cash flow — — — (1) (1) (1) (4) (7) (5) (5)
Balance, $m
Balance, $m Working capital — — — (1) (1) (1) 9 4 4 6
Total debt — — — 1 0 0 0 — 0 0
Net debt — — — 1 0 0 (9) (4) (4) (6)
Shareholders’ equity — — — (1) (1) (1) 9 5 5 7
Returns, %
Returns, % ROA — — — 0.00 (1,643.94) (3,870.44) (110.69) (88.04) (101.78) (68.11)
ROIC — — — 0.00 0.00 0.00 0.00 (262.02) (300.05) (432.65)
ROE — — — 0.00 23.85 168.48 (141.62) (95.90) (114.35) (78.51)
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026

Charts ten years each

Virax Biolabs Group Limited vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NTBLQ Notable Labs, Ltd. $2.4M — (loss-making) — (loss-making) −96.88% (below 0%: shrinking) n/m −26.63% (below 0%: shrinking) 100.00% (269,000.00%) Compare
MTNB Matinas Biopharma Holdings, Inc. $2.4M — (loss-making) — (loss-making) +365,433.33% (above 0%: growing) n/m +9.15% (above 0%: growing) 0.00% 0.00% Compare
BPTSY Biophytis SA Sponsored ADR $2.4M — (loss-making) — — n/m +53.15% (above 0%: growing) 0.00% — Compare
WINT Windtree Therapeutics, Inc. $2.4M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m +1.12% (above 0%: growing) 0.00% 0.00% Compare
KAPA Kairos Pharma, Ltd. $2.3M — (loss-making) — — n/m −25.71% (below 0%: shrinking) — 0.00% Compare
VRAX Virax Biolabs Group Limited $2.2M — (loss-making) — (loss-making) — −855.56% (below 0%: shrinking) +32.24% (above 0%: growing) (53.57%) 0.00%
CLSDQ Clearside Biomedical, Inc. $2.2M — (loss-making) — (loss-making) −80.64% (below 0%: shrinking) n/m +8.15% (above 0%: growing) 100.00% (3,502.49%) Compare
BRTX Biorestorative Therapies, Inc. $2.0M — (loss-making) — (loss-making) −7.20% (below 0%: shrinking) n/m −35.26% (below 0%: shrinking) 68.10% (14,593.53%) Compare
PPBT Purple Biotech Ltd. Sponsored ADR $2.0M — (loss-making) — (loss-making) — n/m −62.10% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $2.3M — — −80.64% — −12.29% 0.00% 0.00%

All 614 Biotechnology stocks →

Virax Biolabs Group Limited (VRAX) key facts

  • Concern: Virax Biolabs Group Limited reported a net loss of $5.0 million, or a loss of $12.64 per share, for fiscal 2026.
  • Strength: Virax Biolabs Group Limited’s revenue for fiscal 2026 (year ended March 2026) was $12,400.00, up 96.8% from fiscal 2025.
  • Virax Biolabs Group Limited (VRAX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, VRAX traded at $1.45, a market capitalization of $2.2 million.
  • Return on equity was −78.5% and debt-to-equity 0.00.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −5.30 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

Virax Biolabs Group Limited (VRAX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/VRAX · Data as of Mar 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com